376 participants
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
- Study Type:
- OBSERVATIONAL
- Last Updated:
- 2025-12-05
- Start Date:
- 2023-12-28
- Completion:
- 2027-06-30
Conditions
- HR+HER2- Advanced Breast Cancer
Interventions
- OTHER
No Results Yet